A5049749922- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Neutropenia and Cancer Infections
- Blood groups and transfusion
- HER2/EGFR in Cancer Research
- Chronic Lymphocytic Leukemia Research
- Diabetic Foot Ulcer Assessment and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Complement system in diseases
- Chronic Myeloid Leukemia Treatments
- Biosimilars and Bioanalytical Methods
- Blood disorders and treatments
- Renal Diseases and Glomerulopathies
- Transplantation: Methods and Outcomes
- Estrogen and related hormone effects
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Brain Metastases and Treatment
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Pneumothorax, Barotrauma, Emphysema
- Cancer-related gene regulation
- Synthesis and bioactivity of alkaloids
- Blood Coagulation and Thrombosis Mechanisms
Rochester General Hospital
2022-2025
Unity Health System
2022-2024
The University of Texas MD Anderson Cancer Center
2024
Moffitt Cancer Center
2024
Nepal Medical College Teaching Hospital
2021
Immunocompromised individuals with hematological malignancy have increased risk for poor outcomes and death from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This special population may mount a suboptimal response to vaccination. We assessed the effectiveness of tixagevimab cilgavimab (Evusheld), monoclonal antibody combination against SARS-CoV-2, in conjunction standard preventative measures, at preventing symptomatic incident infection.Patients aged 18 years older...
Abstract Background: The horizon of Trastuzumab Deruxtecan (T-DXd), an antibody-drug conjugate, has been expanding. After its promising results in HER2-positive/HER2-low Breast cancer, it on trial for other cancers, such as HER2-negative breast Gastrointestinal, lung, colorectal, urothelial, etc., and shown clinical trials. However, there have reports pulmonary adverse events associated with T-DXd, including interstitial lung disease (ILD) pneumonitis. Understanding the occurrence...
Abstract Background: Breast cancer brain metastasis (bcbm) is associated with limited survival. There a paucity of clinical trials and real-world data on the survival disease interval [primary breast (pbc) to metastatic (mbc) or bcbm] bcbm patients. We performed retrospective study comparing overall (OS) intervals (INT) between date pbc surgery, diagnoses mbc, among 3 subtypes bc in patients bcbm. Methods: The informatics team generated preliminary list history who were treated at Wilmot...
e23325 Background: Proteasome inhibitors (PI) are a class of drugs used in the treatment Multiple Myeloma. The FDA has approved three PIs for this indication (Bortezomib, Carfilzomib, and Ixazomib). Various studies, case reports have described occurrence chalazion with Bortezomib use subsequent discontinuation therapy but it’s association other from remains poorly understood. Methods: We conducted retrospective pharmacovigilance study using Adverse Event Reporting System database to analyze...
e24027 Background: Patients with multiple myeloma (MM) are at increased risk of cardiovascular events secondary to its complications and adverse effects pharmacotherapy. However, data on in-hospital outcomes MM acute myocardial infarction (AMI) is limited due the clinical scenario being relatively uncommon. Thus, we conducted a retrospective study investigate resource utilization AMI admissions in patients. Methods: We extracted from National Inpatient Sample (NIS) Database 2016 2020....
e19531 Background: Multiple myeloma (MM) exhibits a disproportionately higher prevalence among African American individuals. Various factors contribute to the disease's progression, severity, and prognosis. This analysis presents real-world data from National Cancer Database (NCDB) 2010 2020. Methods: Cohort of 241,446 MM patients between 2020 were analyzed. Demographic variations, including age, gender, insurance status, educational attainment, median household income, examined....
e19515 Background: Proteasome inhibitors (PI) are a class of drugs that used in the treatment Multiple Myeloma. There currently three PIs (Bortezomib, Carfilzomib, and Ixazomib) approved by FDA for this indication. Peripheral neuropathy has been described as one their most common side effects but association with another life-threatening neurological disorder, Posterior Reversible Encephalopathy Syndrome (PRES), remains poorly understood. Methods: We conducted retrospective pharmacovigilance...
e14005 Background: Patients with Metastatic Breast Cancer (MBC) and brain metastasis (BM) have poor prognosis. There is a lack of data on the effects timing MBC diagnosis [de novo (d) vs recurred (r) MBC] BM [dBM later onset (lo) BM] overall survival (OS). We conducted natural history-type study to investigate these among patients. Methods: The for this retrospective single institute was extracted from database patients diagnosed Jan 2010 June 2021. Definitions: dMBC= at initial (Dx); rMBC=...
e12529 Background: EMC is a biphasic neoplasm of the breast and comprises malignant components derived from both luminal epithelium myoepithelium. Most published data on consists individual case reports, hence survival outcomes prognosis are not clearly defined to guide evidence‐based management. We aimed evaluate clinical characteristics, outcomes, prognostic factors in patients with EMC. Methods: All women histologic diagnosis irrespective age stage at till 2018 National Cancer Database...
e14684 Background: Immune checkpoint inhibitors (ICIs) are increasingly used to treat multiple cancers uncovering varieties of immune-related adverse events (irAEs). ICI-related haemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory syndrome caused by exaggerated activation macrophages and cytotoxic T cells resulting in fatal hematological toxicity multi-organ damage. Methods: We conducted retrospective analysis reported cases HLH patients treated with using data from the...
Breast cancer is the most common among women worldwide, and estrogen receptor-positive (ER+) breast accounts for a significant proportion of cases. While various treatments are available, endocrine therapies often first-line treatment this type cancer. However, development drug resistance poses challenge in managing disease. ESR1 mutations have been identified as mechanism therapy ER+ The first-generation selective receptor degrader (SERD) fulvestrant has shown some activity against mutant...